e-learning
resources
London 2016
Tuesday, 06.09.2016
Novel insights into the treatment of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT)
Courtney Crim (Research Triangle Park, United States of America), Courtney Crim, Robert Brook, Julie Anderson, Sally Kilbride, Peter Calverley, Bartolome Celli, Fernando Martinez, Jørgen Vestbo, Julie Yates, David Newby
Source:
International Congress 2016 – Novel insights into the treatment of COPD
Session:
Novel insights into the treatment of COPD
Session type:
Oral Presentation
Number:
3312
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Courtney Crim (Research Triangle Park, United States of America), Courtney Crim, Robert Brook, Julie Anderson, Sally Kilbride, Peter Calverley, Bartolome Celli, Fernando Martinez, Jørgen Vestbo, Julie Yates, David Newby. Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT). Eur Respir J 2016; 48: Suppl. 60, 3312
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
The influence of NIV on the pulse wave velocity in patients with the exacerbation of COPD
Source: Annual Congress 2013 –COPD treatment
Year: 2013
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Effects of pulmonary rehabilitation (PR) on arterial stiffness in patients with COPD: The CIROCO study
Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation
Year: 2011
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011
Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations
Year: 2013
Acute effects of tiotropium (T), salmeterol (S) and formoterol (F) on arterial blood gases (ABGs) in patients with stable COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 576s
Year: 2005
Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD)
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Pulse wave velocity in patients with COPD comorbid with arterial hypertension
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts)
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003
Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept